Open Label Phase II Trial of Cabozantinib in Patients withMetastatic Castrate Resistant Prostate Cancer (mCRPC) andKnown Amplifications or Activating Mutations in Gene Targets of Cabozantinib whohave Received Prior Anti Androgen Therapy
Study of Cabozantinib in Patients with Prostate Cancer who Previously Received Anti-Androgen Therapy
Sponsor: Weill Cornell
Enrolling: Male and Female Patients
IRB Number: AAAT7368
U.S. Govt. ID: NCT04631744
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of prostate cancer. Cabozantinib (Cometriq, Cabometyx) is an oral medication that blocks activity of specific proteins in the body. It is approved by the Food and Drug Administration (FDA) for use in patients with medullary thyroid carcinoma and advanced renal cell carcinoma but is not approved to treat prostate cancer.
Investigator
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with prostate cancer? Yes No
Have you previously received Anti Androgen Therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE